| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
81.50(B) |
| Last
Volume: |
7,436,599 |
Avg
Vol: |
8,754,576 |
| 52
Week Range: |
$65.27 - $87.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 259 |
| Guru Rank Value : 4.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
12,230 |
25,472 |
38,458 |
80,792 |
| Total Sell Value |
$890,904 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
3 |
5 |
9 |
14 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wold Olsen Per |
Director |
• • – |
2021-05-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,936 |
102,060 |
|
- |
|
| Barton Jacqueline K |
Director |
• • – |
2021-05-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,936 |
15,676 |
|
- |
|
| Mercier Johanna |
Chief Commercial Officer |
• • – |
2021-05-04 |
4 |
S |
$66.09 |
$1,288,547 |
D/D |
(19,496) |
8,068 |
|
-8% |
|
| Whitley Richard James |
Director |
• • – |
2021-05-03 |
4 |
S |
$64.57 |
$1,309,655 |
D/D |
(20,282) |
31,122 |
|
-8% |
|
| Whitley Richard James |
Director |
• • – |
2021-05-03 |
4 |
OE |
$20.65 |
$418,722 |
D/D |
20,282 |
51,404 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2021-03-11 |
4 |
AS |
$63.36 |
$94,153 |
D/D |
(1,486) |
29,166 |
|
8% |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2021-03-10 |
4 |
D |
$63.91 |
$327,411 |
D/D |
(5,123) |
142,013 |
|
- |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,800 |
147,136 |
|
- |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2021-03-10 |
4 |
D |
$63.91 |
$104,748 |
D/D |
(1,639) |
14,079 |
|
- |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,455 |
15,718 |
|
- |
|
| Mercier Johanna |
Chief Commercial Officer |
• • – |
2021-03-10 |
4 |
D |
$63.91 |
$91,711 |
D/D |
(1,435) |
27,564 |
|
- |
|
| Mercier Johanna |
Chief Commercial Officer |
• • – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,025 |
28,999 |
|
- |
|
| Dickinson Andrew D |
Chief Financial Officer |
• • – |
2021-03-10 |
4 |
D |
$63.91 |
$113,185 |
D/D |
(1,771) |
34,930 |
|
- |
|
| Dickinson Andrew D |
Chief Financial Officer |
• • – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,794 |
36,701 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2021-03-10 |
4 |
D |
$63.91 |
$70,748 |
D/D |
(1,107) |
30,652 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,593 |
31,759 |
|
- |
|
| Wilfong Diane E |
SVP, Controller & CAO |
• • – |
2021-03-10 |
4 |
D |
$63.91 |
$38,921 |
D/D |
(609) |
18,825 |
|
- |
|
| Wilfong Diane E |
SVP, Controller & CAO |
• • – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,025 |
19,434 |
|
- |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2021-03-01 |
4 |
D |
$62.46 |
$1,537,765 |
D/D |
(24,620) |
136,336 |
|
- |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2021-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
54,286 |
160,956 |
|
- |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2021-02-15 |
4 |
A |
$56.86 |
$20,696 |
D/D |
364 |
12,263 |
|
- |
|
| Dickinson Andrew D |
Chief Financial Officer |
• • – |
2021-02-15 |
4 |
A |
$56.86 |
$20,696 |
D/D |
364 |
32,907 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2021-02-15 |
4 |
A |
$56.86 |
$18,990 |
D/D |
334 |
29,166 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2021-02-10 |
4 |
AS |
$67.41 |
$133,135 |
D/D |
(1,975) |
28,832 |
|
-0% |
|
| Wilfong Diane E |
SVP, Controller & CAO |
• • – |
2021-02-10 |
4 |
D |
$67.29 |
$13,256 |
D/D |
(197) |
17,409 |
|
- |
|
2493 Records found
|
|
Page 10 of 100 |
|
|
0.74 (1.12%) 
